Business
AZN: first-quarter 2020 results
AZN: first-quarter 2020 results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n RNS Number : 2394L\n AstraZeneca PLC\n 29 April 2020\n \n \n \n AstraZeneca PLC\n 29 April 2020 07:00 BST\n \n First-quarter 2020 results\n Robust results in unprecedented times; leveraging scientific expertise in the fight against COVID-19\n \n \n \n AstraZeneca delivered a quarter of strong revenue and profit growth, reflecting the immense efforts of supply-chain, commercial and other colleagues around the world to get vital medicines to patients. As part of the fight, the Company has rapidly responded to the pandemic, firstly in China and then globally.\n \n Pascal Soriot, Chief Executive Officer, commented:\n \"Our focus ensured another quarter of strong growth across every therapy area and region. The new medicines performed extremely well, and our pipeline continued to deliver. Standouts included landmark news for Tagrisso, Farxiga and Koselugo, our latest oncology medicine. The progress made on all fronts provides confidence that we will, once again, meet our full-year commitments.\n \n I could not be prouder of how the AstraZeneca team has responded to the challenges of COVID-19. We moved quickly to maintain continuity of care, contribute to society, and use our scientific expertise to fight the pandemic. We hope our efforts to protect organs from damage, mitigate the cytokine storm and the associated hyperinflammatory state, and target the virus prove to be successful.\"\n \n COVID-19\n \n The Company donated nine million face masks to support healthcare workers around the world, delivered in collaboration with the World Economic Forum's COVID Action Platform. AstraZeneca also contributed to the UK Government's testing effort with a dedicated site in Cambridge operated in collaboration with the University of Cambridge and GlaxoSmithKline plc (GSK), with a goal to deliver 30,000 tests a day in May 2020.\n \n \n \n \n The Company has mobilised research efforts to find new ways to help target the virus, reduce the cytokine storm, arising from an overactive immune response, and potentially protect organs. As part of the effort to target the virus, the Company is identifying novel SARS-CoV-2-neutralising monoclonal antibodies that can be used for treatment, as well as a prophylaxis against viral infection.\n \n \n \n AstraZeneca is evaluating the use of Calquence, appr...